Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
August 09, 2018 - N°20180222862

Or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of formula i as tdo2 inhibitors.
Electrode placement and stimulation based on brown adipose tissue temperature
Oregon Health & Science University
August 09, 2018 - N°20180221665

Systems and methods for spinal cord electrode placement and spinal cord stimulation their use for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a spinal cord stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue may be monitored, e.g., via a supraclavicular temperature ...
Intragastric device
Obalon Therapeutics, Inc.
August 09, 2018 - N°20180221633

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of obesity using non-daily administration of 6-o-(4-dimethylaminoethoxy) cinnamoyl fumagillol
Zafgen, Inc.
August 09, 2018 - N°20180221328

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a metap-2 inhibitor.. .
Method of treating melanocortin-4 receptor pathway-associated disorders
Rhythm Pharmaceuticals, Inc.
August 02, 2018 - N°20180215790

The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (mc4r) agonist.. .
Tetrahydro-azepinoquinolines as agonists of the 5-ht2c receptor
Sunnylife Pharma, Inc.
August 02, 2018 - N°20180215752

Certain tetrahydro-azepinoquinolines of structural formula i are agonists of the mammalian 5-ht2c receptor, and, in particular, are selective agonists of the mammalian 5-ht2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-ht2c receptor, such as obesity, obesity-related conditions, and ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Formulations for weight loss and methods of use
Golo Llc
August 02, 2018 - N°20180214502

A weight loss composition including banaba leaf extract, apple fruit extract, rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, salacia extract, berberine, inositol, or mixtures thereof.
5-ht2c receptor agonists and compositions and methods of use
Arena Pharmaceuticals, Inc.
August 02, 2018 - N°20180214455

Provided in some embodiments are compounds of formula a, as defined herein, that modulate the activity of 5-ht2c receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, ...
Anti-laminin4 antibodies specific for lg4-5
Prothena Biosciences Limited
July 26, 2018 - N°20180208646

The invention provides antibodies that specifically bind to the lg4-5 modules of the g domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue.
Carbamate compounds and methods of making and using same
The Scripps Research Institute
July 26, 2018 - N°20180208568

This disclosure provides compounds and compositions which may be modulators of magl and/or abhd6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as ...
Composition containing nad for preventing and treating obesity or impaired glucose tolerance
University Of Ulsan Foundation For Industry Cooperation
July 26, 2018 - N°20180207190

A pharmaceutical composition containing nicotinamide adenine dinucleotide (nad) as an active ingredient for preventing and treating obesity or impaired glucose tolerance, a food composition, and a method for preventing and treating obesity or impaired glucose tolerance using the same is disclosed. The nad remedies an abnormal food intake pattern of an obese animal model induced by the intake of a ...
Compositions and methods for treating, preventing, or alleviating obesity or related diseases
Korea University Research And Business Foundation
July 26, 2018 - N°20180207120

A composition comprising azelaic acid as an active ingredient suppresses accumulation of lipids in adipose tissue and improves lipid metabolism in adipose tissue.. .
Modified apparatus for food extraction and obesity treatment
Ethicon, Inc.
July 26, 2018 - N°20180207014

A device that is inserted through the abdominal wall and into the digestive tract of a human is disclosed. The device may be placed through a method such as percutaneous endoscopic gastrostomy (peg).
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer
The Uab Research Foundation
July 19, 2018 - N°20180201565

Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer..
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
July 19, 2018 - N°20180200334

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Inhibitory compositions
Inqpharm Group Sdn Bhd
July 19, 2018 - N°20180200274

The present invention related to a composition comprising a pentose and one or more polyphenolic compounds, and to the use of said compositions for managing or reducing glucose and/or lipid absorption in a subject, and/or calorie absorption from dietary protein, carbohydrate and/or fat in a subject. The composition may be used to inhibit one or more enzymes ...
Heteroaromatic compounds and their use as dopamine d1 ligands
July 19, 2018 - N°20180200253

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds and the uses of such compounds for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild ...
Passive caloric bypass device
Ethicon, Inc.
July 19, 2018 - N°20180200094

A novel medical device for treating obesity is disclosed. The device is inserted through the oral cavity and into the digestive tract of a human.
Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof
President And Fellows Of Harvard College
July 12, 2018 - N°20180194768

Provided herein are compounds of formulae (rl), (i), (ii), (iii), (iv), and (v), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity).
Compounds for the treatment of obesity and methods of use thereof
The Children's Medical Center Corporation
July 12, 2018 - N°20180194709

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
The University Of British Columbia
July 12, 2018 - N°20180193413

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive ...
Loading